The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH AL 2020 | Targeted therapy for AML
Juliette Lambert
• 30 Jun 2020
Juliette Lambert, MD, Versailles Hospital, Le Chesnay, France, talks on treatment options for acute myeloid leukemia (AML), including gemtuzumab ozogamicin. Dr Lambert highlights the importance of finding the place for gemtuzumab ozogamicin among targeted therapies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
